Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted Other Non-Current Assets of $11.7 million for Q2 2026, down 12.5% on a QoQ basis from $13.4 million in Q1 2026, and up 6.96% year-over-year from $11.0 million in Q2 2025.
Analysis
Dr Reddys Laboratories (RDY) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories has reported Other Non-Current Assets for 18 years, with the latest figure at $11.7 million in Q2 2026.
- On a quarterly basis, Other Non-Current Assets rose 6.96% year-over-year to $11.7 million in Q2 2026; TTM through Jun 2026 was $11.7 million, a 6.96% increase from a year earlier, with the FY2026 full-year figure at $13.0 million, up 8.33% from the prior year.
- Other Non-Current Assets was $11.7 million for Q2 2026 at Dr Reddys Laboratories, down from $13.4 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $23.6 million in Q2 2022, with the low at $9.7 million in Q1 2023.
- Average Other Non-Current Assets over 5 years is $14.9 million, with a median of $12.9 million recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 106.35% in 2022, then tumbled 57.59% in 2023.
- Over 5 years, Other Non-Current Assets stood at $22.3 million in 2022, then sank by 39.25% to $13.5 million in 2023, then climbed by 18.9% to $16.1 million in 2024, then fell by 23.59% to $12.3 million in 2025, then dropped by 4.65% to $11.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $11.7 million (Q2 2026), $13.4 million (Q1 2026), and $12.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.63 Bn | 38.97 Bn | 2.15 Bn | 1.79 Bn |
| 2 | Viatris | 19.19 Bn | 18.30 Bn | 1.46 Bn | 1.06 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 11.74 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | 80.67 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 520.30 Mn | 2.10 Bn | 358.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 14.42 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 11.62 Mn |
| 8 | Amphastar Pharmaceuticals | 995.52 Mn | 705.40 Mn | 93.47 Mn | 33.39 Mn |
| 9 | Fennec Pharmaceuticals | 404.35 Mn | 363.10 Mn | 17.15 Mn | 666,000.00 |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | 169,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.74 Mn |
| Mar 31, 2026 | 13.41 Mn |
| Dec 31, 2025 | 12.31 Mn |
| Sep 30, 2025 | 12.29 Mn |
| Jun 30, 2025 | 10.97 Mn |
| Mar 31, 2025 | 11.22 Mn |
| Dec 31, 2024 | 16.11 Mn |
| Sep 30, 2024 | 18.03 Mn |
| Jun 30, 2024 | 19.89 Mn |
| Mar 31, 2024 | 19.65 Mn |
| Dec 31, 2023 | 13.55 Mn |
| Sep 30, 2023 | 9.82 Mn |
| Jun 30, 2023 | 9.99 Mn |
| Mar 31, 2023 | 9.73 Mn |
| Dec 31, 2022 | 22.30 Mn |
| Sep 30, 2022 | 22.59 Mn |
| Jun 30, 2022 | 23.56 Mn |
| Mar 31, 2022 | 11.89 Mn |
| Dec 31, 2021 | 12.52 Mn |
| Sep 30, 2021 | 11.16 Mn |